Primo Biotechnology (Primo) and SHINE Technologies, LLC (SHINE), a global leader in nuclear medicine production, today announced a strategic partnership. This includes a supply and exclusive distribution agreement bringing SHINE’s high-purity therapeutic isotope, Ilumira (n.c.a. lutetium-177, Lu-177), to Taiwan and the wider Asia-Pacific market. This collaboration strengthens Primo’s market position, accelerates advancements in radioligand theranostics (RLT), and propels the region towards advanced precision medicine.
Ilumira is a breakthrough in nuclear medicine, offering more precise and effective treatment options for challenging cancers. Primo aims to provide comprehensive cancer care solutions, from early diagnosis to advanced treatment, across the Asia-Pacific region.
This partnership enhances Primo and SHINE’s competitive standing. Primo gains exclusive distribution rights for Ilumira in Taiwan and sales rights in Japan, South Korea, and Singapore, plus priority access to SHINE’s other therapeutic isotopes.
SHINE’s Cassiopeia facility in Janesville, Wisconsin, is North America’s largest producer of n.c.a. Lu-177. Expansion plans will double annual output to 200,000 doses, meeting growing global demand and supporting Primo’s regional expansion.
“This collaboration is a key step in bringing precision cancer care to patients. Our partnership with SHINE ensures a reliable supply of high-quality isotopes, advancing cancer treatment in the Asia-Pacific region,” stated Dr. Ya-Yao Huang, Primo Biotechnology’s CEO.
“Demand for high-purity Lu-177 is rising as more patients benefit from targeted cancer therapies. Primo’s regional presence and expertise make them the ideal partner to deliver reliable, high-quality isotopes in this crucial market,” said Todd Caccamo, SHINE Technologies’ chief revenue officer.
About SHINE
Janesville, Wisconsin-based SHINE pioneers next-generation fusion technology for medical isotope production, specializing in n.c.a. lutetium-177 and soon molybdenum-99. Their fusion-based approach advances healthcare and sustainable energy.
For more information, visit .
About Primo Biotechnology
Primo Biotechnology is a leader in Asia’s nuclear medicine sector, developing and producing high-precision radiopharmaceuticals. Using molecular imaging and innovative therapies, Primo provides precise diagnostics and personalized cancer treatments. Their vision, Future in Precision, underscores their commitment to healthcare advancements.
Learn more at and follow Primo on and .
Media Contact:
Primo Biotechnology Co., Ltd.
Sunny Chen
Marketing Manager
| +8862-2537-1160
“`
